Gene | Title | Epigenetic modulation | Cancer |
---|---|---|---|
ZDHHC1 | DNA methylation downregulated ZDHHC1 suppresses tumor growth by altering cellular metabolism and inducing oxidative/ER stress-mediated apoptosis and pyroptosis | DNA methylation | Various cancers |
GSDME | Antitumor effect of simvastatin in combination with DNA methyltransferase inhibitor on gastric cancer via GSDME-mMediated pyroptosis | DNA methylation | Gastric cancer |
GSDME | Programming cell pyroptosis with biomimetic nanoparticles for solid tumor immunotherapy | DNA methylation | Solid tumor |
GSDMD | Elevated methionine flux drives pyroptosis evasion in persister cancer Cells | DNA methylation | Persister Cancer |
GSDME | Gasdermin E deficiency attenuates acute kidney injury by inhibiting pyroptosis and inflammation | DNA methylation | Colorectal tumours |
GSDME | Large-scale analysis of DFNA5 methylation reveals its potential as biomarker for breast cancer | DNA methylation | Breast cancer |
GSDME | Postsurgical wound management and prevention of triple-negative breast cancer recurrence with a pryoptosis-inducing, photopolymerizable hydrogel | DNA methylation | Breast cancer |
GSDMA/B/D/E | GSDMs are potential therapeutic targets and prognostic biomarkers in clear cell renal cell carcinoma | DNA methylation | Clear cell renal cell carcinoma |
GSDMD | Co-delivery of nigericin and decitabine using hexahistidine-metal nanocarriers for pyroptosis-induced immunotherapeutics | DNA methylation | Bladder cancer |
Caspase−1 | G9A promotes tumor cell growth and invasion by silencing CASP1 in non-small-cell lung cancer cells | Histone modification | Lung cancer |
Caspase−1 | PRMT5 regulates cell pyroptosis by silencing CASP1 in multiple myeloma | Histone modification | Multiple myeloma |
Caspase−1 | Inhibition of BRD4 prevents proliferation and epithelial-mesenchymal transition in renal cell carcinoma via NLRP3 inflammasome-induced pyroptosis | Histone modification | Renal cancer |
Caspase−1 | Death by histone deacetylase inhibitor quisinostat in tongue squamous cell carcinoma via apoptosis, pyroptosis, and ferroptosis | Histone modification | Tongue cancer |
Caspase−1 | 4,5-Dimethoxycanthin−6-one is a novel LSD1 inhibitor that inhibits proliferation of glioblastoma cells and induces apoptosis and pyroptosis | Histone modification | Glioblastoma |
microRNA−125b/Caspase−1 | Tanshinone IIA regulates microRNA‑125b/foxp3/caspase‑1 signaling and inhibits cell viability of nasopharyngeal carcinoma | Non-coding RNAs | Nasopharynx cancer |
miR−145/GSDMD | Tanshinone II A enhances pyroptosis and represses cell proliferation of HeLa cells by regulating miR−145/GSDMD signaling pathway | Non-coding RNAs | Cervical cancer |
miR−182/NLRP3 | Stat5 inhibits NLRP3-mediated pyroptosis to enhance chemoresistance of breast cancer cells via promoting miR−182 transcription | Non-coding RNAs | Breast cancer |
MiR-495/NLRP3 | NLRP3 Inflammasome Activation by MicroRNA−495 Promoter Methylation May Contribute to the Progression of Acute Lung Injury | Non-coding RNAs | Acute lung injury |
LncRNA MEG3/NLRP3 | Cisplatin Induces Pyroptosis via Activation of MEG3/NLRP3/caspase−1/GSDMD Pathway in Triple-Negative Breast Cancer | Non-coding RNAs | Breast cancer |
LncRNA TCONS−14,036/NLRP3 | The sodium new houttuyfonate suppresses NSCLC via activating pyroptosis through TCONS−14,036/miR−1228−5p/PRKCDBP pathway | Non-coding RNAs | Lung cancer |
METTL3/YTHDF2/NLRP3 | LncRNA LINC00969 promotes acquired gefitinib resistance by epigenetically suppressing of NLRP3 at transcriptional and posttranscriptional levels to inhibit pyroptosis in lung cancer | m6A modification | Lung cancer |
METTL14/YTHDF2 | Methyltransferase-like 14 suppresses growth and metastasis of renal cell carcinoma by decreasing long noncoding RNA NEAT1 | m6A modification | Renal cell carcinoma |
YTHDF1/GSDMD | YTHDF1 alleviates sepsis by upregulating WWP1 to induce NLRP3 ubiquitination and inhibit caspase−1-dependent pyroptosis | m6A modification | Sepsis |
METTL14/TINCR/NLRP3 | METTL14 suppresses pyroptosis and diabetic cardiomyopathy by downregulating TINCR lncRNA | m6A modification | Diabetic cardiomyopathy |
YTHDC1/ Caspase−1 | LncRNA FENDRR with m6A RNA methylation regulates hypoxia-induced pulmonary artery endothelial cell pyroptosis by mediating DRP1 DNA methylation | m6A modification | Hypoxic pulmonary hypertension |
METTL3/ Caspase−1 | The METTL3/MALAT1/PTBP1/USP8/TAK1 axis promotes pyroptosis and M1 polarization of macrophages and contributes to liver fibrosis | m6A modification | Liver fibrosis |
METTL3/ NLRP3 | Total Flavones of Abelmoschus manihot Ameliorates Podocyte Pyroptosis and Injury in High Glucose Conditions by Targeting METTL3-Dependent m6A Modification-Mediated NLRP3-Inflammasome Activation and PTEN/PI3K/Akt Signaling | m6A modification | Diabetic nephropathy |